Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1847 results
November 2022
-
Press release
New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years
Results from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (… -
Press release
Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics
EUR 50m planned investment to support increased manufacturing capacity for finished dosage form penicillins, the leading class of antibiotics worldwideNew project brings total planned investment into… -
Story People and Culture
A scientist from the start – Q&A with NIBR President Fiona Marshall
October 2022
-
Ad hoc release
Novartis maintains growth momentum and confirms FY’22 Group guidance
Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven by key growth brands including: Entresto (+31% cc),… -
Ad hoc release
Novartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im dritten Quartal um +4% kWk1 (–4% USD): Innovative Medicines (IM) steigerte den Umsatz um +4% kWk (–3% USD), getragen von… -
Ad hoc release
Novartis maintient sa dynamique de croissance et confirme les prévisions de l’exercice 2022 pour le Groupe
Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T3 en hausse de +4% tcc1 (-4% USD) Innovative Medicines (IM) : hausse du chiffre d’affaires de +4% tcc (-3% USD),… -
Ad hoc release
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
Ad hoc announcement pursuant to Art. 53 LRPhase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal nocturnal hemoglobinuria (PNH) patients… -
Press release
Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer
Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and… -
Featured News
World Sight Day 2022: Raising awareness on the importance of eye health
Through the Avoidable Blindness Program, Novartis is working with partners to strengthen eye health in sub-Saharan Africa.
-
Story People and Culture
In neuroscience, “an inflection point in knowledge and technology”
-
Story Patient Perspectives
Let’s Talk About the C Word: Navigating a cancer diagnosis and the life beyond it with Leanne Pero
Leanne Pero discusses her experiences of life before, during and after breast cancer, and how it inspired her to advocate for herself and others like her.